GGrantIndex
← Leaderboards

Hasan Mukhtar

Case Western Reserve University

$12,132,209
Attributed
$12,132,209
Total exposure
14
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.1M · FY200519
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$12,132,209 · 14

By mechanism

R01$9,752,775 · 5
T32$1,271,966 · 2
R21$364,210 · 1
P30$304,902 · 2
R03$294,750 · 2
P50$143,606 · 2

Top collaborators

No co-investigators on record.

Most similar at Case Western Reserve University

Same institution · by research overlap

Others in their field

Top investigators on “Chemoprevention

Research focus

ChemopreventionIn VitroIn VivoPathway InteractionsInhibitor/AntagonistApoptosisSignal TransductionNeoplastic CellCellsCell GrowthAndrogensBaseMalignant NeoplasmsCancer PreventionPhosphotransferasesMouse ModelCell ProliferationSignal PathwayMolecularSkinPreventionMalignant Neoplasm Of ProstateFlavonoidsAffect

Grant awards (56)

Targeting PI3K/Akt/mTOR for the management of psoriasis$336,600
R01 · FY2019 · AR · contact PI
Targeting PI3K/Akt/mTOR for the management of psoriasis$336,600
R01 · FY2018 · AR · contact PI
Targeting PI3K/Akt/mTOR for the management of psoriasis$336,600
R01 · FY2017 · AR · contact PI
Targeting PI3K/Akt/mTOR for the management of psoriasis$336,600
R01 · FY2016 · AR · contact PI
Targeting PI3K/Akt/mTOR for the management of psoriasis$336,600
R01 · FY2015 · AR · contact PI
Developing Fisetin for the Managment of Prostate Cancer$308,138
R01 · FY2015 · CA · contact PI
Defining the role of miR-30 in human skin$165,550
R21 · FY2015 · AR · contact PI
Developing Fisetin for the Managment of Prostate Cancer$8,529
R01 · FY2015 · CA · contact PI
Caspase-14 and the Treatment of Psoriasis$314,344
R01 · FY2014 · AR · contact PI
Developing Fisetin for the Managment of Prostate Cancer$298,894
R01 · FY2014 · CA · contact PI
Defining the role of miR-30 in human skin$198,660
R21 · FY2014 · AR · contact PI
Developing Fisetin for the Managment of Prostate Cancer$52,308
R01 · FY2014 · CA · contact PI
Caspase-14 and the Treatment of Psoriasis$304,722
R01 · FY2013 · AR · contact PI
Developing Fisetin for the Managment of Prostate Cancer$289,649
R01 · FY2013 · CA · contact PI
Investigative Dermatology Training Program at University of Wisconsin-Madison$220,580
T32 · FY2013 · AR · contact PI
Developing Fisetin for the Managment of Prostate Cancer$53,926
R01 · FY2013 · CA · contact PI
Caspase-14 and the Treatment of Psoriasis$320,760
R01 · FY2012 · AR · contact PI
Developing Fisetin for the Managment of Prostate Cancer$308,138
R01 · FY2012 · CA · contact PI
Investigative Dermatology Training Program at University of Wisconsin-Madison$199,534
T32 · FY2012 · AR · contact PI
Caspase-14 and the Treatment of Psoriasis$320,760
R01 · FY2011 · AR · contact PI
Developing Fisetin for the Managment of Prostate Cancer$308,138
R01 · FY2011 · CA · contact PI
Pomegranate for Chemoprevention and Chemotherapy of Prostate Cancer$270,921
R01 · FY2011 · CA · contact PI
Investigative Dermatology Training Program at University of Wisconsin-Madison$185,777
T32 · FY2011 · AR · contact PI
Caspase-14 and the Treatment of Psoriasis$334,125
R01 · FY2010 · AR · contact PI
Pomegranate for Chemoprevention and Chemotherapy of Prostate Cancer$279,300
R01 · FY2010 · CA · contact PI
Investigative Dermatology Training Program at University of Wisconsin-Madison$191,996
T32 · FY2010 · AR · contact PI
Pomegranate for Chemoprevention and Chemotherapy of Prostate Cancer$279,300
R01 · FY2009 · CA · contact PI
Investigative Dermatology Training Program at University of Wisconsin-Madison$186,242
T32 · FY2009 · AR · contact PI
Pomegranate for Chemoprevention and Chemotherapy of Prostate Cancer$279,300
R01 · FY2008 · CA · contact PI
Green Tea in Chemoprevention of Prostate Cancer$241,431
R01 · FY2008 · CA · contact PI
Molecular Targets for Prevention of Prostate Cancer by Green Tea$306,342
R01 · FY2007 · CA · contact PI
Pomegranate for Chemoprevention and Chemotherapy of Prostate Cancer$279,300
R01 · FY2007 · CA · contact PI
Green Tea in Chemoprevention of Prostate Cancer$241,431
R01 · FY2007 · CA · contact PI
Mechanisms for Acquired Changes in Prostate Growth Regulation$143,606
P50 · FY2007 · DK · contact PI
Molecular Targets for Prevention of Prostate Cancer by *$315,491
R01 · FY2006 · CA · contact PI
Green Tea in Chemoprevention of Prostate Cancer$248,642
R01 · FY2006 · CA · contact PI
Molecular Targets for Prevention of Prostate Cancer by *$323,083
R01 · FY2005 · CA
Green Tea in Chemoprevention of Prostate Cancer$254,625
R01 · FY2005 · CA
Molecular Targets for Prevention of Prostate Cancer by *$323,083
R01 · FY2004 · CA
Green Tea in Chemoprevention of Prostate Cancer$254,625
R01 · FY2004 · CA
Molecular Targets for Prevention of Cancer by Green Tea$323,083
R01 · FY2003 · CA
Oleandrin: A Novel Skin Cancer Chemopreventive Agent$72,750
R03 · FY2003 · CA
Novel Targets for Chemoprevention of Prostate Cancer$0
P50 · FY2003 · DK
CANCER CHEMOPREVENTIVE MECHANISMS OF GREEN TEA$154,939
R01 · FY2002 · CA
Training in Investigative and Molecular Dermatology$124,949
T32 · FY2002 · AR
Oleandrin: A Novel Skin Cancer Chemopreventive Agent$72,750
R03 · FY2002 · CA
PROSTATE CANCER CHEMOPREVENTION BY COX 2 INHIBITION$72,750
R03 · FY2002 · CA
CANCER CHEMOPREVENTIVE MECHANISMS OF GREEN TEA$57,837
R01 · FY2002 · CA
CANCER CHEMOPREVENTIVE MECHANISMS OF GREEN TEA$209,094
R01 · FY2001 · CA
TRAINING IN INVESTIGATIVE AND MOLECULAR DERMATOLOGY$79,380
T32 · FY2001 · AR
PROSTATE CANCER CHEMOPREVENTION BY COX 2 INHIBITION$76,500
R03 · FY2001 · CA
CORE--ANIMAL EXPERIMENTATION$45,924
P30 · FY2001 · AR
CANCER CHEMOPREVENTIVE MECHANISMS OF GREEN TEA$205,517
R01 · FY2000 · CA
CORE--ATHYMIC ANIMAL FACILITY$180,108
P30 · FY2000 · CA
TRAINING IN INVESTIGATIVE AND MOLECULAR DERMATOLOGY$83,508
T32 · FY2000 · AR
CORE--ATHYMIC ANIMAL FACILITY$78,870
P30 · FY2000 · CA